Podcasts about Gyn

Et si la vraie prévention commençait bien avant la maladie ?Pourquoi attendons-nous souvent que le corps nous alerte pour agir ?Peut-on rester en pleine forme plus longtemps, simplement en apprenant à écouter les signaux faibles avant qu'ils ne deviennent des problèmes ?Ce sont les questions que soulève le docteur Marc Naett. Gynécologue de formation, aujourd'hui spécialiste de médecine fonctionnelle et de longévité, il s'intéresse à cette zone souvent invisible entre la santé idéale et la maladie déclarée.Spécialiste des hormones, il décrypte des phénomènes que beaucoup vivent sans les comprendre : la baisse de fertilité après 35 ans, la pré-ménopause souvent ignorée, la fatigue persistante malgré des analyses normales, et les idées reçues autour de la testostérone.Ensemble, nous explorons les clés concrètes pour vivre non seulement plus longtemps, mais mieux.Bonne écoute ✨Chapitrage 00:00 – Qu'est-ce que la médecine fonctionnelle ?04:00 – Fertilité : pression, timing et sur-interventionnisme10:30 – Micronutrition : l'impact invisible sur l'ovule13:00 – Périménopause : les premiers signes ignorés18:50 – Œstrogènes et cancer : le grand malentendu26:00 – Vieillissement hormonal : peut-on le ralentir ?35:30 – Andropause : mythe ou réalité ?37:00 – Thyroïde et fatigue chronique : pourquoi “tout est normal”52:00 – Hormones et peur collective : faut-il essayer ?Notes et références de l'épisode ✨ Pour retrouver Marc Naett : Sur le site de la Clinique Hertoghe Via son adresse mail marcnaett@skynet.be #Menopause #Andropause #Hormones #MedecineFonctionnelle #FatigueChronique #SanteFeminine #SanteMasculine #Thyroide #Longévité #Prévention #PaulineLaigneau #PodcastSantéVous pouvez consulter notre politique de confidentialité sur https://art19.com/privacy ainsi que la notice de confidentialité de la Californie sur https://art19.com/privacy#do-not-sell-my-info.

Mit dem Code „staYoung“ erhalten Sie VITAQ®️ Omega3 1.100 für 49,00 €. inklusive MwSt. und Versand. Link: https://aspriva.com/stayoungEinmalige Verwendung pro Person. Maximal 2 Produkte. Gültig bis 31. März 2026 oder solange der Vorrat reicht.   Eine Packung VITAQ®️ Omega3 1.100 enthält 90 Kapseln mit insgesamt 99.630 mg Omega-3-Fettsäuren. Pro Kapsel: 1.107 mg Omega-3, davon 667 mg EPA und 333 mg DHA.  ***In dieser Episode spreche ich mit dem Endokrinologen und Gynäkologen Dr. Jörg Puchta vom Hormonzentrum an der OPA in München. Er vertritt eine klare Position: Die Datenlage zur modernen, bioidentischen Hormonersatztherapie sei deutlich besser als ihr Ruf – und die langfristigen Folgen eines unbehandelten Hormonmangels würden häufig unterschätzt. Wir diskutieren die kardiovaskulären Risiken nach der Menopause, den Einfluss von 17-Beta-Östradiol auf Stammzellen, Gehirn und Immunsystem sowie die Frage, ob die historische WHI-Studie heute noch als Argument gegen HRT taugt. Diese Folge ordnet die wissenschaftliche Evidenz neu ein – mit Blick auf gesunde Langlebigkeit, Präventionsmedizin und individuelle Risikobewertung.  In dieser Folge sprechen wir u.a. über folgende Themen:  ​Warum die WHI-Studie die heutige HRT-Praxis nur begrenzt abbildet ​Unterschied zwischen synthetischen Präparaten und bioidentischem 17-Beta-Östradiol ​Transdermale versus orale Applikation und ihre metabolischen Folgen ​Kardiovaskuläre Risiken nach der Menopause ​Einfluss von Östrogen auf Stammzellen und Knochenmark ​Zusammenhang zwischen Hormonmangel und Alzheimer-Risiko ​Immunologische Effekte von Östrogen und Beobachtungen aus der Covid-Pandemie ​Osteoporose, Knochengesundheit und Gewebealterung ​Progesteron: Indikation, Nutzen und mögliche Risikosignale ​DHEA und Pregnenolon als Nebenspieler der Hormontherapie ​Individuelle Risikoprüfung vor Therapiebeginn ​HRT im höheren Lebensalter: Beginn oder Fortführung nach 60+  Weitere Informationen zu Dr. Jörg Puchta findest du hier:  https://www.hormonzentrum-an-der-opa.de linkedin.com/in/jörg-puchta  Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g   Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin.  STY-166 

Im Newsweek-Ranking thront sie aktuell auf dem vierten Platz der weltbesten Einrichtungen für Gynäkologie und Geburtshilfe. Die Frauenklinik am Universitätsklinikum Tübingen genießt eine Vorreiterstellung und ist laut Baubürgermeister Cord Soehlke der Grund dafür, warum auf den Geburtsurkunden so vieler Menschen von der Region Neckar-Alb bis in den Schwarzwald die Universitätsstadt als Geburtsort steht. Die hohe Nachfrage forderte einen Anbau an das bereits bestehende Klinikum. | Videos in der RTF1 Mediathek: www.rtf1.tv | RTF1 - Wissen was hier los ist! |

Après Dakar, Kinshasa, Lomé, La Havane et Abidjan, l'équipe de Priorité Santé poursuit sa série de portraits, à la rencontre de la future génération des médecins du Sud. À Conakry, trois futurs médecins se confient et partagent leur parcours, leurs attentes comme l'origine de leur vocation au service de la santé des autres. Cette émission donne également l'occasion de rencontrer le Doyen de la Faculté de médecine et de visiter les lieux.  Pour cette 4è et dernière émission enregistrée, à Conakry, nous vous proposons de regarder vers le futur et de partir à la rencontre de celles et de ceux, qui « nous soigneront demain » ! Ils partagent aujourd'hui leur temps entre les cours et les stages, et nous expliquent à quand remonte leur décision de devenir médecin, et comment leur entourage a réagi à cet engagement, qui est aussi un choix de vie…  Est-ce qu'il y a eu des critiques ou des freins ?  Que pensent-ils du soin de l'hôpital et quelles sont leurs perspectives d'avenir ?   Nous vous proposons une rencontre, à trois voix… Ils se prénomment Aïssatou, Abdoul Aziz et Cécile Raphaëlle, aujourd'hui, inscrits à la Faculté des Sciences et Techniques de la santé de l'Université Gamal Abdel Nasser de Conakry. Nous vous proposons également de découvrir leur cadre d'apprentissage théorique et scientifique, à l'occasion d'une visite guidée par Pr Mohamed Cissé, doyen de la Faculté des sciences et techniques de la santé de l'Université Gamal Abdel Nasser.  Avec :  Pr Mohamed Cissé, chef du service de Dermatologie MST du CHU de Donka à Conakry. Doyen de la Faculté des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée  Aïssatou Kamano, étudiante en 5è année d'odontologie, à la Faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry, en Guinée   Cécile Raphaëlle Macos, étudiante en 57 année de Médecine, à la faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée   Abdoul Aziz Baldé, étudiant en 4è année DES de Gynécologie obstétrique, à la Faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée.   Programmation musicale :  ► One Time - Wo Bravo    ► Collectif d'artistes Guinéens - La Guinée notre Paradis  

Après Dakar, Kinshasa, Lomé, La Havane et Abidjan, l'équipe de Priorité Santé poursuit sa série de portraits, à la rencontre de la future génération des médecins du Sud. À Conakry, trois futurs médecins se confient et partagent leur parcours, leurs attentes comme l'origine de leur vocation au service de la santé des autres. Cette émission donne également l'occasion de rencontrer le Doyen de la Faculté de médecine et de visiter les lieux.  Pour cette 4è et dernière émission enregistrée, à Conakry, nous vous proposons de regarder vers le futur et de partir à la rencontre de celles et de ceux, qui « nous soigneront demain » ! Ils partagent aujourd'hui leur temps entre les cours et les stages, et nous expliquent à quand remonte leur décision de devenir médecin, et comment leur entourage a réagi à cet engagement, qui est aussi un choix de vie…  Est-ce qu'il y a eu des critiques ou des freins ?  Que pensent-ils du soin de l'hôpital et quelles sont leurs perspectives d'avenir ?   Nous vous proposons une rencontre, à trois voix… Ils se prénomment Aïssatou, Abdoul Aziz et Cécile Raphaëlle, aujourd'hui, inscrits à la Faculté des Sciences et Techniques de la santé de l'Université Gamal Abdel Nasser de Conakry. Nous vous proposons également de découvrir leur cadre d'apprentissage théorique et scientifique, à l'occasion d'une visite guidée par Pr Mohamed Cissé, doyen de la Faculté des sciences et techniques de la santé de l'Université Gamal Abdel Nasser.  Avec :  Pr Mohamed Cissé, chef du service de Dermatologie MST du CHU de Donka à Conakry. Doyen de la Faculté des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée  Aïssatou Kamano, étudiante en 5è année d'odontologie, à la Faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry, en Guinée   Cécile Raphaëlle Macos, étudiante en 57 année de Médecine, à la faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée   Abdoul Aziz Baldé, étudiant en 4è année DES de Gynécologie obstétrique, à la Faculté́ des sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry en Guinée.   Programmation musicale :  ► One Time - Wo Bravo    ► Collectif d'artistes Guinéens - La Guinée notre Paradis  

Wie oft hoffen wir, dass endlich jemand sieht, wie schlecht es uns geht?Dass der Partner es merkt. Die Familie. Freundinnen. Dass jemand sagt: „Du brauchst Pause.“ Und manchmal warten wir so lange darauf, dass wir uns selbst dabei verlieren.In dieser Folge geht es um einen Wendepunkt: Nicht länger still leiden und darauf hoffen, dass andere unsere Not erkennen – sondern lernen, für uns selbst einzustehen.Denn du bist nicht nur Mama. Du bist auch Frau. Mensch. Seele. Und du darfst dich wieder spüren.In dieser Folge sprechen wir darüber:warum so viele Mamas darauf warten, „gerettet“ zu werden – und warum das oft nicht passiertweshalb Erschöpfung uns stumm macht und Bedürfnisse verschlucktwarum es kein Egoismus ist, Hilfe einzufordernwie du lernst, Grenzen zu setzen, ohne dich schuldig zu fühlenwie du wieder Kontakt zu dir selbst bekommst – Schritt für Schrittwarum du nicht erst zusammenbrechen musst, um ernst genommen zu werdenDiese Folge ist eine Einladung, wieder bei dir anzukommen.Nicht perfekt. Nicht stark. Sondern echt.Du darfst dich wieder wichtig nehmen. Und du darfst dein Leben zurückholen – Stück für Stück.---Erste Anlaufstellen bei chronischer Erschöpfung (seriös & hilfreich)Medizinische Abklärung (wichtiger erster Schritt)Wenn du über Wochen oder Monate erschöpft bist, sprich mit:Hausärztin / Hausarzt (Blutbild, Schilddrüse, Eisen/Ferritin, Vitamin D/B12, Entzündungswerte etc.)Gynäkologin / Gynäkologe (besonders nach Schwangerschaft/Geburt)ggf. Psychotherapeutin / Psychiaterin, wenn depressive Symptome oder Burnout-Anzeichen da sindInfo der Bundesärztekammer:https://www.bundesaerztekammer.deHilfe bei Erschöpfung / Depression / BurnoutStiftung Deutsche Depressionshilfehttps://www.deutsche-depressionshilfe.deTelefonSeelsorge (24/7, anonym & kostenlos)https://www.telefonseelsorge.de

Today, I have the privilege of connecting with Dr. Sara Gottfried! Dr. Sara is a board-certified physician who graduated from Harvard and MIT. She practices evidence-based, integrative, precision, and functional medicine. She is a Clinical Assistant Professor in the Department of Integrative Medicine and Nutritional Sciences at Thomas Jefferson University and Director of Precision Medicine at the Marcus Institute of Integrative Health. She has written four New York Times bestselling books, including her latest, Women, Food and Hormones.  Dr. Sara is one of my favorite doctors in integrative medicine and GYN! In this episode, we dive into the infodemic, how stress impacts hormones, the impact of age-related changes on hormonal regulation, alcohol, and gender differences with ketogenic lifestyles. We discuss some lesser-known hormones, including growth hormone, and how to support them properly. We touch on disordered eating, how trauma influences our relationship with food, epigenetics, and the role of a lifetime relationship with food. We also look at methylation, glutathione, detox reactions, supporting physical detoxification, and our toxic diet culture. I hope you benefit as much from this episode as I did!  IN THIS EPISODE YOU WILL LEARN: Dr. Sara explains what an infodemic is and how it has affected how she communicates with her patients.  What happens to our hormones as we age? The impact of stress on hormone regulation. Dr. Sara busts the myth that testosterone is a male hormone and discusses what testosterone means for women. How does alcohol consumption impact women's hormones? Why do men tend to have an easier time with the ketogenic diet than women? The dramatic changes that occur in women's bodies as they transition from perimenopause to menopause. Looking at the interrelationship between trauma, stress, and autoimmunity. The changes that occur with growth hormones as we age. How trauma affects the genes. How disordered eating impacts metabolism. How to support physical detoxification naturally, without going to extremes. How to address weight-loss plateaus. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Sara Gottfried On her ⁠website⁠ ⁠Facebook⁠, ⁠Instagram⁠ Dr. Sara's books are available on https://www.saragottfriedmd.com/ and ⁠Amazon.⁠

Kennst du dieses Gefühl, dass du nie wirklich Pause hast – selbst dann nicht, wenn alle schlafen?Dass du funktionierst, aber innerlich leer bist? Und dass du dich manchmal unfassbar allein fühlst, obwohl du gar nicht alleine bist?In dieser Folge sprechen wir darüber, warum so viele Mamas heute erschöpft und einsam sind – und warum das nichts mit persönlichem Versagen zu tun hat.Du bekommst keine perfekten Lösungen, sondern etwas viel Wichtigeres: Verständnis, Entlastung und das Gefühl, nicht falsch zu sein.In dieser Folge erfährst du:warum Einsamkeit nicht bedeutet, „keine Menschen zu haben“warum Erschöpfung mehr ist als Müdigkeitwelche unsichtbaren Belastungen viele Mamas tragenwarum das „Dorf“ heute oft fehltwarum Schuldgefühle so häufig dazugehörenweshalb du nicht schwach bist, sondern überlastetDiese Folge ist Seelenbalsam für alle, die gerade nur noch funktionieren.Einsame & erschöpfte Mama – Warum betrifft das so viele? (1/2)Kennst du dieses Gefühl, dass du nie wirklich Pause hast – selbst dann nicht, wenn alle schlafen?Dass du funktionierst, aber innerlich leer bist? Und dass du dich manchmal unfassbar allein fühlst, obwohl du gar nicht alleine bist?In dieser Folge sprechen wir darüber, warum so viele Mamas heute erschöpft und einsam sind – und warum das nichts mit persönlichem Versagen zu tun hat.Du bekommst keine perfekten Lösungen, sondern etwas viel Wichtigeres: Verständnis, Entlastung und das Gefühl, nicht falsch zu sein.In dieser Folge erfährst du:warum Einsamkeit nicht bedeutet, „keine Menschen zu haben“warum Erschöpfung mehr ist als Müdigkeitwelche unsichtbaren Belastungen viele Mamas tragenwarum das „Dorf“ heute oft fehltwarum Schuldgefühle so häufig dazugehörenweshalb du nicht schwach bist, sondern überlastetDiese Folge ist Seelenbalsam für alle, die gerade nur noch funktionieren.Erste Anlaufstellen bei chronischer Erschöpfung (seriös & hilfreich)Medizinische Abklärung (wichtiger erster Schritt)Wenn du über Wochen oder Monate erschöpft bist, sprich mit:Hausärztin / Hausarzt (Blutbild, Schilddrüse, Eisen/Ferritin, Vitamin D/B12, Entzündungswerte etc.)Gynäkologin / Gynäkologe (besonders nach Schwangerschaft/Geburt)ggf. Psychotherapeutin / Psychiaterin, wenn depressive Symptome oder Burnout-Anzeichen da sindInfo der Bundesärztekammer:https://www.bundesaerztekammer.deHilfe bei Erschöpfung / Depression / BurnoutStiftung Deutsche Depressionshilfehttps://www.deutsche-depressionshilfe.deTelefonSeelsorge (24/7, anonym & kostenlos)https://www.telefonseelsorge.de

In dieser Folge spreche ich mit Dr. Sheila de Liz, Fachärztin für Gynäkologie und eine der profiliertesten Stimmen zur modernen Hormonmedizin. Im Mittelpunkt steht die Hormonersatztherapie in den Wechseljahren – ein Thema, das bis heute stark emotionalisiert und von alten Studien, Ängsten und Missverständnissen geprägt ist. Wir sprechen darüber, warum die Angst vor Brustkrebs wissenschaftlich nicht mehr haltbar ist, welche gesundheitlichen Vorteile eine zeitgemäße, individuell begleitete Hormontherapie haben kann und wo ihre klaren Grenzen liegen. Diese Folge ordnet ein, klärt auf und zeigt, warum die Wechseljahre kein Schicksal sein müssen, sondern ein Wendepunkt für gesunde Langlebigkeit sein können. In dieser Folge sprechen wir u.a. über folgende Themen: - Warum gilt die Angst vor Brustkrebs durch Hormonersatztherapie heute als überholt? -Welche Fehler prägten die WHI-Studie nachhaltig die Leitlinien? - Welche gesundheitlichen Vorteile zeigt moderne Hormonersatztherapie langfristig? - Welche Rolle spielt Hormonersatztherapie bei Osteoporose-Prävention? - Warum beginnt Prävention idealerweise bereits in der Perimenopause? - Für welche Frauen ist Hormonersatztherapie klar kontraindiziert? - Welche Unterschiede bestehen zwischen Tabletten und transdermaler Therapie? - Welche Bedeutung haben Progesteron und Testosteron für Frauen? - Können Rezeptoren im höheren Alter wieder ansprechbar werden? - Was leisten pflanzliche Alternativen realistisch – und was nicht? Weitere Informationen zu Dr. Sheila de Liz findest du hier: https://www.dr-de-liz.de/ /⁠ Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin. STY-167

HashiMotion® hat geöffnet! Bis zum 8.2. kannst Du Dir Deinen Platz sichern! Ab dem 9.2. geht es dann offiziell los! Sei auch Du in unserem 16 Wochen Erfolgsprogramm mit dabei! HIER sicherst Du Dir Deinen Platz und bekommst alle Informationen zum Programm!   Dein Hashimoto Kick Starter Guide für 0 Euro! Meine Bücher: Neustart für die Schilddrüse Soforthilfe bei Schilddrüsenunterfunktion und Hashimoto ---------------------- Die Links von Dany: Website   Instagram   LinkedIn ---------------- In dieser Folge spreche ich mit Dr. med. Daniela Bach, vielen auch bekannt als Doc Dany – ehemalige Gynäkologin, Women's Health Educator und Gründerin der Glückssprechstunde. Daniela hat viele Jahre in Klinik und Praxis gearbeitet und dabei immer wieder dasselbe erlebt: Zu wenig Zeit. Zu wenig Mitgefühl. Zu wenig Raum für die wirklich wichtigen Fragen von Frauen. Statt sich weiter einem System anzupassen, das echte Prävention kaum zulässt, hat sie einen neuen Weg eingeschlagen – mit einem ganzheitlichen Ansatz für Frauengesundheit, der Medizin, Nervensystem, Zykluswissen, Sexualmedizin und Selbstfürsorge verbindet.

„Bei meiner ersten Periode bin ich vor Schmerzen ohnmächtig geworden. Meine Frauenärztin meinte: 'Das gehört zum Frausein dazu. Da musst du durch.' Da war ich 12 Jahre alt.” Ganze zwölf Jahre dauert es dann auch, bis Vivian die Diagnose Endometriose bekommt. Die Erkrankung betrifft 10 bis 15 Prozent aller Frauen und kann neben wehenähnlichen Schmerzen und weiteren Symptomen auch zu Unfruchtbarkeit führen. In dieser Folge erzählt Vivian von ihrer Geschichte und was ihr heute hilft, mit der Krankheit umzugehen. In der Forschung zu Endometriose hat sich in den letzten Jahren einiges getan. Über Ursachen, Diagnose und Behandlung klärt Prof. Sylvia Mechsner auf. Sie ist Gynäkologin, leitet das Endometriose-Zentrum der Charité in Berlin und forscht selbst zur Erkrankung. Wir sprechen auch über Medical Gaslighting und warum es vor allem strukturelle Veränderungen braucht, um Patientinnen besser zu helfen.

Stellt euch eine Welt vor, in der es nicht vom Einkommen oder dem Wohnort abhängt, wie gesund wir sind oder wie alt wir werden. Eine Welt, in der der Satz „Armut macht krank“ nicht mehr Realität ist. Genau an dieser Vision arbeitet Monty Dhanjal. Monty ist Mediziner*in*, hat Ethnologie und Kulturwissenschaften studiert und promoviert aktuell an der Uniklinik Leipzig zu Diskriminierung in der Gynäkologie. Außerdem arbeitet Monty als Gesundheitsberater*in* bei der Poliklink Leipzig – einem Ort, an dem Gesundheitsversorgung neu gedacht wird: niedrigschwellig, solidarisch, interdisziplinär und mitten im Stadtteil. In dieser Folge sprechen wir darüber: - warum Gesundheit immer noch so stark an sozialen Faktoren hängt - wo unser Gesundheitssystem Menschen im Stich lässt und wie Lücken geschlossen werden können - wie Versorgung aussieht, die Strukturen statt Symptome in den Blick nimmt - warum das Ziel der Poliklinik erreicht wäre, wenn es sie eines Tages nicht mehr bräuchte Monty teilt eindrucksvolle Geschichten aus dem Arbeitsalltag, die zeigen, wie ungleich Chancen auf Gesundheit in Deutschland verteilt sind – und was passiert, wenn Menschen endlich ernst genommen werden. Eine Folge über (soziale) Gerechtigkeit, Visionen und praktische Lösungen, die im Alltag von Menschen wirklich etwas verändern.

Manche Menschen prägen eine Region, ohne dass sie im Mittelpunkt stehen. Und mein heutiger Gast gehört dazu. Er war viele Jahrzehnte als Gynäkologe in Nassau tätig und hat unzählige Frauen medizinisch und menschlich begleitet. Zusätzlich war er über lange lange Zeit auch als leitender Notarzt im Rhein-Lahn-Kreis im Einsatz. In dieser Folge geht es um seinen Weg in die Medizin, um Erfahrungen aus Praxis und Notfalldienst, um Veränderungen im Arztberuf – und um die Frage, was gute Medizin eigentlich ausmacht. Ein Gespräch mit Dr. Frank Abraham!

In this episode of The Roxanne Show, I sit down with Dr. Lorna Brudie—former GYN oncologist and Medical Director at Excel Medical—for a vital conversation about women's health, hormones, and why our healthcare system has it backwards..After nearly three decades treating cancer, Dr. Brudie explains why she shifted from reactive medicine to proactive care—and how hormone optimization plays a critical role in disease prevention, longevity, and quality of life. We unpack the lasting impact of the 2002 Women's Health Initiative, the misconceptions it created around hormone therapy, and what women were never fully told.This conversation is about understanding your body, asking better questions, and recognizing that women's healthcare doesn't have to begin at crisis—it can start with awareness, education, and prevention.EPISODE HIGHLIGHTS:Why hormones affect everything from metabolism to cancer riskThe difference between reactive and proactive medicineWhat the 2002 hormone study got wrongHow bioidentical hormones support long-term healthWhy informed women make healthier, more empowered choices⭐️YOUR SUPPORT MATTERS: Please: Subscribe + leave 5⭐️Star rating +review HEREEnjoy! xRxFIND ME ON:️INSTAGRAMSUBSTACKYOUTUBEXTHREADSFIND DR LORNA ON:IGWEB

Fibroid care: how it was, how it's changing, and where it's headed next. In this episode of BackTable OBGYN, hosts Dr. Mark Hoffman and Dr. Amy Park welcome minimally invasive GYN surgeon Dr. Arleen Song to discuss the evolving landscape of fibroid care. --- SYNPOSIS Dr. Song, a veteran in the field with nearly 20 years of experience, shares her journey from Michigan to Duke, current treatments in fibroid management, and the importance of personalized care. The team explores new surgical techniques, the role of medical therapies such as Ella GnRH antagonists, and the importance of patient education. They also address challenges such as access to care, the significance of research funding, and the evolving understanding of fibroid genetics and long-term management. This episode provides a comprehensive overview of the state of fibroid care and the strides being made in this vital aspect of women's health. --- TIMESTAMPS 00:00 - Introduction02:21 - Evolution of Fibroid Treatment05:50 - Advancements in Minimally Invasive Surgery08:47 - Longitudinal Care and Personalized Treatment13:00 - Modern Approaches to Fibroid Treatment21:15 - New Technologies and Procedures27:01 - Preoperative Assessment and Imaging31:15 - Preoperative Counseling and Risk Assessment33:14 - Medications for Fibroid and Endometriosis37:59 - Challenges in Access to Care38:43 - Racial Disparities in Fibroid Research42:35 - The Importance of Specialized Care49:22 - Future Directions in Fibroid Treatment

Monika ist Gynäkologin und Aktivistin. Um Frauen zu helfen, die sexuelle Gewalt erfahren haben, reiste sie Anfang der 1990er nach Bosnien ins Kriegsgebiet. Für ihr unermüdliches Engagement musste sie auch einen persönlichen Preis zahlen, erzählt sie. Braun, Jessica www.deutschlandfunkkultur.de, Plus Eins

Wenn man ein grundsätzliches Verständnis für die Funktion von Östradiol und Progesteron hat, kann man die hormonellen Übergangsphasen im Leben einer Frau viel besser verstehen – und die vermeintlich unerklärlichen Symptome, mit denen sie einher gehen können. Das gilt nicht nur in der Perimenopause, sondern auch in der Zeit danach, der Postmenopause. Diana im Gespräch mit Gynäkologin, Autorin und Medfluencerin Dr. Judith Bildau über schlechten Schlaf nach der letzten Regelblutung, urogenitale Beschwerden, die erst einige Jahre später kommen, Hormondosierungen 60plus und welche Vorsorgeuntersuchungen sie für besonders unterschätzt hält.INFOS ZUR FOLGE:Hier geht's zur Website von Dr. Judith Bildau.Hier geht es zu Judith auf Instagram.Hier geht es zu Judiths aktuellem Buch, das im Oktober bei Droemer Knaur erschienen ist: „Body in Balance“.Hier geht es zu Judiths letztem Buch: „Raus aus dem Hormonkarussell“, erschienen bei Gräfe und Unzer GU im April 2024.Hier geht es zu ihrer Online-Sprechstunde bei wexxeljahre.de.Hier geht es zum Newsletter "Saisonwechsel" von der BRIGITTE.Hier geht es zum meno_brigitte-Insta-Account.Hier geht es zu Dianas Instagram.Hier geht es zu Julias Instagram.Auch interessant:Hier geht es zur MENO AN MICH Folge Nr. 40 "Untenrum Unbehagen: Scheidentrockenheit" mit Dr. Katrin Schaudig.Hier geht es zu Folge Nr. 85 "Kaputte Nächte – schlechter Schlaf in der Gynäkologie-Praxis" mit Dr. Katrin Schaudig.Hier geht es zur Folge Nr. 132 "Und danach? Die Postmenopause." mit Dr. Katrin Schaudig.Hier geht es zur Folge Nr. 16 "Auch wach? Besser schlafen in der Lebensmitte" mit Dr. Beate Paterok.+++ Weitere Infos zu unseren Werbepartnern findet Ihr hier: https://linktr.ee/menoanmich +++WEITERE ANGEBOTE aus der BRIGITTE Redaktion:Krafttraining-Kurs 50 plus der BRIGITTE Academy: Forever Fit On Demand Kurs von BRIGITTE ACADEMY.Masterclass Finanzen (aus unserer Eigenwerbung in dieser Folge, der Early Bird Rabatt gilt bis zum 8. September): academy.brigitte.de/masterclass?utm_source=menoanmich&utm_medium=podcast&utm_campaign=mcf-premium-kh11&utm_term=shopSkin-Code-Kurs mit Dermatologin Dr. Yael Adler: brigitte.de/meno-skinOn Demand Video-Kurs "Wechseljahre: Wissen, was hilft": https://academy.brigitte.de/course/wechseljahre?utm_source=podcast&utm_medium=meno&utm_campaign=wechseljahreKostenloses Webinar Rentenlücke berechnen: https://academy.brigitte.de/webinar-aufzeichnung-rentenluecke-berechnenETF Kurs: https://academy.brigitte.de/course/etf-kurs?utm_source=menoanmich&utm_medium=podcast&utm_campaign=etf-kurs-mEs gibt auch einen MENO AN MICH-Rabattcode, MENO15 (gilt für viele BRIGITTE-Angebote). Ihr habt Anregungen, wollt uns Eure Geschichte erzählen oder selbst bei uns zu Gast im Podcast sein? Dann schreibt uns beiden persönlich, worüber Ihr gern mehr wissen würdet, was Euch bewegt, rührt, entsetzt und Freude macht an podcast@brigitte.de. Wir freuen uns auf Euch! Und bewertet und abonniert unseren Podcast gerne auch auf Spotify, iTunes, Amazon Music oder Audio Now. Noch mehr spannende Beiträge findet Ihr zudem auf Brigitte.de sowie dem Instagram- oder Facebook-Account von BRIGITTE –schaut vorbei! +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.htmlUnsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

Das Versprechen der ewigen Jugend und Schönheit lasse sie kalt, dachte «Input»-Autorin Julia Lüscher lange. Bis sich, mit knapp vierzig, ein Gedanke in ihren Kopf schlich: «So eine Botoxspritze, was kostet die eigentlich?» Selbstbestimmt älter werden mitten im Beauty-Boom – wie gelingt das? «Ich kann nicht glauben, dass ich das gerade mache», sagt Hanne mit 36, als sie sich zum ersten Mal botoxen lässt. «Sich dagegen zu wehren ist schwierig», findet auch Ärztin Marlies Baertsch, die seit zwei Jahren in ihrer Praxis Botoxbehandlungen anbietet. Die Forschung zum Mittleren Alter zeigt: Ab vierzig erleben viele Menschen eine Phase der Unsicherheit und Neuorientierung. «Der perfekte Nährboden für die profitorientierte Beauty-Industrie, die ewige Jugend verspricht», sagt die Politologin und Aktivistin Emilia Roig. Ein «Input» von Julia Lüscher über den Drahtseilakt im eigenen Gesicht. ___________________ Habt ihr Feedback, Fragen oder Wünsche? Wir freuen uns auf eure Nachrichten an input@srf.ch – und wenn ihr euren Freund:innen und Kolleg:innen von uns erzählt. ____________________ 00:00 - 01:50 Intro 02:00 - 08:00 Besprechung in der Arztpraxis 08:00- 09:40 Botox-Boom, Unseriosität und Tabu 09:40 - 11:40 Eitelkeit, Scham und Zweifel: Hanne im Botox-Dilemma 11:42 - 16:19 Strenge gesetzliche Regulierung und milliardenschweres Geschäft 16:50 - 19:10 Hanne wagt den Schritt 19:20 - 21:25 Dana und die fehlende Reaktion im Gesicht nach Botox 21:50 - 26:30 Unsicherheit und Beauty-Industrie: Politologin Emilia Roig zum Älterwerden 26:30 - 30:10 Forschung zum Älterwerden und neue Freiheiten ab vierzig 30:11 - 34:58 Selbstbestimmt älter werden - wie ist das möglich? 35:00 - 36:38 Fazit ____________________ In dieser Episode zu hören - Hanne, Dana, Ranja, Solenne - Marlies Bärtsch, Gynäkologin - Emilia Roig, Politolgin und Autorin - Christina Röcke, UZH, Healthy Longevity Center ____________________ - Autorin: Julia Lüscher - Publizistische Leitung: Anita Richner ____________________ Das ist «Input»: Dem Leben in der Schweiz auf der Spur – mit all seinen Widersprüchen und Fragen. Der Podcast «Input» liefert jede Woche eine Reportage zu den Themen, die euch bewegen.

In dieser neuen Episode greifen wir ein Thema auf, das aktuell viele Frauen bewegt – und gleichzeitig viele Fragen aufwirft: bioidentische Hormone. Gemeinsam mit meiner Gynäkologin Dr. Michaela Fischbach sprechen wir darüber, wann dieser Weg sinnvoll sein kann, wo seine Grenzen liegen und warum es keine pauschalen Antworten gibt. Wir schauen auf unterschiedliche Lebensphasen, auf individuelle Voraussetzungen – und auf das, was Frauen oft nicht hören, bevor sie Hormone einnehmen. Ich hoffe, diese Folge inspiriert dich, mehr auf dich selbst zu achten und dein eigenes Wohlbefinden zur Priorität zu machen. Wenn du etwas Wertvolles mitnehmen konntest, freue ich mich über eine 5-Sterne Bewertung und darüber, wenn du die Episode mit anderen Frauen teilst, die sich auch um ihre Gesundheit kümmern möchten. Fühl dich wohl, deine Kathi

Weil Kopfschmerzen so ein großes Thema sind, und die Folge vom 6. Oktober 2023 so aktuell ist wie am ersten Tag, senden wir sie hier noch einmal – und denken dabei fest an alle Frauen, die während der Feiertage Migräne haben. Alles Gute für Euch, und allen unseren Hörerinnen ein frohes neues Jahr!Kopfschmerzen stehen auf der Symptom-Checkliste für die Wechseljahre, und zwischen 40 und 50 Jahren haben Frauen die meisten Migräneattacken. Diana spricht mit der Gynäkologin, Hormonspezialistin und Migränepatientin Dr. Anneliese Schwenkhagen über stark schwankende Östrogenwerte in der Lebensmitte als Auslöser, warum die heute gängige Hormonersatztherapie mit dem körpereigenen ("bioidentischen") Gestagen Progesteron an den Schmerzattacken nichts verändert und wieso es schonmal hilft, den Gedanken zuzulassen, dass die vertrauten Kopfschmerzen ja auch eine Migräne sein könnten.Hier geht es zum ForeverFit-Kurs aus unserer Werbung, zur Zeit mit 20 Prozent Neujahrsrabatt.INFOS ZUR FOLGE:Hier geht es zu Dr. Anneliese Schwenkhagen im Internet.Hier geht es zu ihrer Hormon Akademie auf Instagram.Hier geht es zum Newsletter "Saisonwechsel" von der BRIGITTE.Hier geht es zum meno_brigitte-Insta-Account.Hier geht es zu Dianas Instagram.Hier geht es zu Julias Instagram.+++ Weitere Infos zu unseren Werbepartnern findet Ihr hier: https://linktr.ee/menoanmich +++ WEITERE ANGEBOTE aus der BRIGITTE Redaktion:Masterclass Finanzen (aus unserer Eigenwerbung in dieser Folge, der Early Bird Rabatt gilt bis zum 8. September): academy.brigitte.de/masterclass?utm_source=menoanmich&utm_medium=podcast&utm_campaign=mcf-premium-kh11&utm_term=shopSkin-Code-Kurs mit Dermatologin Dr. Yael Adler: brigitte.de/meno-skinKrafttraining-Kurs 50 plus der BRIGITTE: Forever Fit On Demand Kurs von BRIGITTE ACADEMYOn Demand Video-Kurs "Wechseljahre: Wissen, was hilft": https://academy.brigitte.de/course/wechseljahre?utm_source=podcast&utm_medium=meno&utm_campaign=wechseljahreKostenloses Webinar Rentenlücke berechnen: https://academy.brigitte.de/webinar-aufzeichnung-rentenluecke-berechnenETF Kurs: https://academy.brigitte.de/course/etf-kurs?utm_source=menoanmich&utm_medium=podcast&utm_campaign=etf-kurs-mEs gibt auch einen MENO AN MICH-Rabattcode, MENO15 (gilt für viele BRIGITTE-Angebote). Ihr habt Anregungen, wollt uns Eure Geschichte erzählen oder selbst bei uns zu Gast im Podcast sein? Dann schreibt uns beiden persönlich, worüber Ihr gern mehr wissen würdet, was Euch bewegt, rührt, entsetzt und Freude macht an podcast@brigitte.de. Wir freuen uns auf Euch! Und bewertet und abonniert unseren Podcast gerne auch auf Spotify, iTunes, Amazon Music oder Audio Now. Noch mehr spannende Beiträge findet Ihr zudem auf Brigitte.de sowie dem Instagram- oder Facebook-Account von BRIGITTE –schaut vorbei! +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

Today, I am delighted to connect with Dr. Sameena Rahman, a board-certified OBGYN and certified menopause practitioner with over a decade of expertise in midlife sexual medicine and concierge gynecology. Dr. Rahman founded the GSM Collective in downtown Chicago to deliver a more personalized patient-first model of health care for women.  In our conversation, we explore how cultural and racial factors influence care for women, particularly during the menopausal transition. We discuss the heart disease risk of women with a baseline of inflammation and insulin resistance, the effects of allostatic load on minority women, why cognitive health is crucial, the impact of alcohol, and why the current medical model is a systemic failure that gaslights women. We also examine the impact of pelvic floor therapy, appropriate pelvic examinations, specific autoimmune vulvar conditions, and how oral contraceptives affect sexual health, and Dr. Rahman shares her recommendations for preventing frailty and loss of independence. I am a big admirer of Dr. Rahman's work and look forward to having her join us again after her new book is published. IN THIS EPISODE, YOU WILL LEARN: Why Hormone Replacement Therapy alone might not solve all menopausal genital issues How pelvic floor issues can even affect women who have not given vaginal births What a routine Pap smear can miss, regarding vulvar and vestibular health What a simple Q-tip test can reveal about vulvar pain How untreated pain can create a cycle of pelvic floor problems How local hormone therapy can target vulvar and vestibular pain where systemic hormones may fall short The benefits of trauma-informed exams  The value of integrating pelvic floor therapy with local hormone treatment  How long-term birth control use might affect vulvar tissue What to consider for balancing contraception with sexual health Bio: Dr. Sameena Rahman Dr. Sameena Rahman is a board-certified OB/GYN, sex-med gynecologist, menopause specialist, and a clinical assistant professor of OB/GYN at the Northwestern Feinberg School of Medicine.  She is the founder of the GYN & Sexual Medicine Collective, a successful concierge practice that emphasizes evidence-based medicine, and an affiliate of Ms. Medicine. Dr. Rahman is dedicated to evaluating and treating each patient with compassion, trauma-informed care, and an awareness of personal bias. Additionally, she hosts the podcast Gyno Girl Presents: Sex, Drugs & Hormones and will release her first book, Brown Girls Disease? A Guide To Sexual Health and Empowerment through a South Asian Lens in 2026.  Connect with Cynthia Thurlow   Follow on⁠ X⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community ⁠(The Midlife Pause/Cynthia Thurlow⁠)⁠ ⁠ Cynthia's⁠ Menopause Gut Book⁠ is on presale now! Cynthia's⁠ Intermittent Fasting Transformation⁠ Book ⁠The Midlife Pause supplement line⁠ Connect with Dr. Sameena Rahman The GSM Collective Dr. Sameena Rahman on Instagram (@gynogirl) Gyno Girl Presents Sex, Drugs and Hormones (Podcast) Resources Find a practitioner to assist with your sexual concerns The International Society for Vulvo Vaginal Diseases The National Vulvodynia Association Prosayla (Female Sexual Health Education)

Gynäkologin Prof. Dr. Marion Kiechle von der Technischen Universität München entwickelt, gefördert vom Bayrischen Gesundheitsministerium, die so genannte W1-Wechseljahreberatung: ein strukturiertes ärztliches Gespräch, das über die Menopause aufklärt und mit der Kasse direkt abgerechnet werden kann. Eine helle Freude für alle Meno-Aktivistinnen, die eine eigene Abrechnungsziffer für die Wechseljahreberatung gefordert hatten. Aber wie läuft die Beratung genau ab? Welchen Nutzen soll sie haben? Wann kommt sie, für die Frauen in Bayern und für alle Versicherten? Und wie sieht es mit anderen Forderungen der #wirsind9millionen-Bewegung aus, werden die jetzt auch erfüllt? Plus: Wie Gyn-Legende Kiechle auf die Meno-Bewegung blicktHier geht es zum SkinCode-Kurs mit Dermatologin Dr. Yael Adler aus unserer Werbung, zur Zeit mit 20 Prozent Weihnachtsrabatt.INFOS ZUR FOLGE:Hier geht es zu Prof. Dr. Marion Kiechle im Internet.Hier geht es zu ihrem Insta-Account.Hier geht es zum Text aus der Süddeutschen Zeitung (aus dem Bayernteil... Danke für den Hinweis, liebe Ira).Eine Landingpage für W1 gibt es noch nicht, wir tragen sie aber nach, sobald sie da ist. Dort kann man sich dann auch für die Studie anmelden.Hier geht es zum Newsletter "Saisonwechsel" von der BRIGITTE.Hier geht es zum meno_brigitte-Insta-Account.Hier geht es zu Dianas Instagram.Hier geht es zu Julias Instagram.+++ Weitere Infos zu unseren Werbepartnern findet Ihr hier: https://linktr.ee/menoanmich +++ WEITERE ANGEBOTE aus der BRIGITTE Redaktion:Masterclass Finanzen (aus unserer Eigenwerbung in dieser Folge, der Early Bird Rabatt gilt bis zum 8. September): academy.brigitte.de/masterclass?utm_source=menoanmich&utm_medium=podcast&utm_campaign=mcf-premium-kh11&utm_term=shopSkin-Code-Kurs mit Dermatologin Dr. Yael Adler: brigitte.de/meno-skinKrafttraining-Kurs 50 plus der BRIGITTE: Forever Fit On Demand Kurs von BRIGITTE ACADEMYOn Demand Video-Kurs "Wechseljahre: Wissen, was hilft": https://academy.brigitte.de/course/wechseljahre?utm_source=podcast&utm_medium=meno&utm_campaign=wechseljahreKostenloses Webinar Rentenlücke berechnen: https://academy.brigitte.de/webinar-aufzeichnung-rentenluecke-berechnenETF Kurs: https://academy.brigitte.de/course/etf-kurs?utm_source=menoanmich&utm_medium=podcast&utm_campaign=etf-kurs-mEs gibt auch einen MENO AN MICH-Rabattcode, MENO15 (gilt für viele BRIGITTE-Angebote). Ihr habt Anregungen, wollt uns Eure Geschichte erzählen oder selbst bei uns zu Gast im Podcast sein? Dann schreibt uns beiden persönlich, worüber Ihr gern mehr wissen würdet, was Euch bewegt, rührt, entsetzt und Freude macht an podcast@brigitte.de. Wir freuen uns auf Euch! Und bewertet und abonniert unseren Podcast gerne auch auf Spotify, iTunes, Amazon Music oder Audio Now. Noch mehr spannende Beiträge findet Ihr zudem auf Brigitte.de sowie dem Instagram- oder Facebook-Account von BRIGITTE –schaut vorbei! +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

This episode brings together the science, the medicine, and the lived experience behind BRCA mutations.  Emily Goldberg, JScreen's Director of Genetic Counseling Services, breaks down what these mutations are, how they're inherited, and what the actual cancer risks look like. Dr. Melissa Frey, a GYN oncologist at Cornell who works closely with high-risk families, walks us through what happens after someone tests positive — from screening to risk-reducing surgeries to the big conversations around fertility and timing. We also hear from Heather Boussi, who shares her powerful story of living with both BRCA1 and BRCA2 mutations. She talks about diagnosis, surveillance, surgeries, and how this all shaped her family-building decisions. Lastly, we look at what BRCA means for men, how that journey differs, and why PGT can still be an option. If you or someone you love is navigating this, we close with places to turn for support: JScreen, Sharsheret, I Was Supposed To Have A Baby, and Stardust (links below). It's a mix of expertise, honesty, and heart — the kind of conversation so many people wish they had heard earlier, especially when faced with such difficult decisions.  Note: This episode is the 4th of a series of 5 that we are collaborating on with Jscreen in 2025.  Take a look at our previous three episodes here : Episode 157: Introduction to Genetics and Infertility Episode 166: Fragile X Syndrome: A Silent Factor in Infertility Episode 185: It's Not Just Her: Male Factor Fertility and Genetics Uncovered Resources: Genetics and Personalized Cancer Prevention Program Facing Our Risk Empowered (FORCE) Jewish Fertility Foundation Stardust Foundation Sharsheret JScreen More about Emily Goldberg: Emily Goldberg serves as the Director of Genetic Counseling Services at jscreen, where she is dedicated to helping individuals understand and manage their genetic health. With dual bachelor's degrees in biology and psychology from Brandeis University and a master's degree in Human Genetics from Sarah Lawrence College, Ms. Goldberg has been a certified genetic counselor since 2011. Prior to joining jscreen, she worked at Montefiore Medical Center in the Bronx, specializing in prenatal and cancer genetics. In addition to her role at jscreen, Ms. Goldberg is committed to education, serving as an Instructor at the Albert Einstein College of Medicine and adjunct faculty at Sarah Lawrence College, where she teaches and mentors future genetic counselors. Her expertise and dedication make her a key member of the jscreen team. Connect with JScreen: - visit their website here - check out their Instagram   More about Melissa Frey, MD: Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine / NewYork Presbyterian Hospital. Dr. Frey's clinical care and research focus on the management of individuals with hereditary cancer syndromes (e.g. BRCA1, BRCA2, Lynch syndrome) and strong family history of breast and gynecologic cancers. She performs gynecologic cancer risk-reducing surgeries and is the principal investigator on several large trials aimed at cancer prevention among high-risk individuals. Dr. Frey has presented her research at national and international meetings and has more than 130 publications in peer-reviewed scientific journals. Connect with Dr. Melissa Frey: - check out her Instagram - view the Genetics and Personalized Cancer Prevention Program website   More about Heather Boussi :  Heather grew up in Westchester, NY and now lives in Englewood, NJ with her husband and three children. Her personal experience with hereditary cancer risk and genetic testing has made her a passionate advocate for awareness, education, and empowerment in women's health. Grounded in faith and family, Heather shares her story to help others approach life's challenges with strength, perspective, and gratitude. Connect with Heather: - check out Heather's Instagram   Connect with us: -Check out our Website -Follow us on Instagram and send us a message -Watch our TikToks -Follow us on Facebook -Watch us on YouTube -Connect with us on LinkedIn

Le gynécologue et la sage-femme sont les interlocuteurs des femmes, sur de multiples questions de santé, pour la prise en charge de nombreuses affections. Cette fonction d'écoute, de conseil et de soins est l'une des composantes indispensables de la santé féminine aux différents âges de leur vie, en particulier à partir de la puberté.  Quels moyens de prévention du cancer du col de l'utérus existent aujourd'hui ? Avec : Pr Namory Keita, past Président immédiat de la SAGO (Société Africaine des Gynécologues-Obstétriciens). Consultant en matière de santé reproductive et mise en œuvre des programmes de lutte contre les cancers gynécologiques Retrouvez l'émission en entier ici : Gynécologie-obstétrique : deux spécialistes répondent aux questions des auditrices

Robert Meier präsentiert ausgewählte Beiträge aus „Kontrafunk aktuell“ im Wochenrückblick. In dieser Woche sprachen wir mit Vadim Derksen, Journalist der „Jungen Freiheit“, über die Angriffe von linksextremen Demonstranten in Gießen, mit Unternehmer Michael Saier über die Kritik am Verband der Familienunternehmer und mit der Fachanwältin für Bank- und Kapitalmarktrecht Kerstin Bontschev über die neuen Ausmaße des „Debanking“ in Deutschland. Außerdem zu Gast waren die Theaterproduzentin Sina Selensky, der Sinologe Jonas Greindberg, Unternehmer Marco Sieber, der Ökonomieprofessor Fritz Söllner, die Sozialwissenschaftlerin Astrid Warburg-Manthey, der Gynäkologe Dr. Armin Breinl und Moriz Jeitler, Student und Obmann der bürgerlichen Aktionsgemeinschaft Jus in Österreich.  

À l'occasion du congrès Pari(s) Santé Femmes qui se tient du 3 au 5 décembre à Paris, nous parlons de la santé des femmes. Contraception, infections, grossesse et accouchement, infertilité… Des médecins spécialisés en gynécologie-obstétrique répondent aux questions des auditrices.   Le gynécologue et la sage-femme sont les interlocuteurs des femmes, sur de multiples questions de santé, pour la prise en charge de nombreuses affections. Cette fonction d'écoute, de conseil et de soins est l'une des composantes indispensables de la santé féminine aux différents âges de leur vie, en particulier à partir de la puberté.  Des spécialistes à l'écoute des femmes  En consultation, les interrogations et les plaintes peuvent concerner aussi bien l'origine de douleurs et la quête d'un soulagement, que le suivi d'une grossesse, un projet d'enfant et, toujours dans le cadre de la santé reproductive, les questions portant sur la contraception ou la fertilité…   Ces professionnels de santé vont également prendre en charge des maladies et infections spécifiques, comme l'endométriose, des cancers féminins (comme celui du sein ou du col de l'utérus).  Écoute et compétence, sans tabou  De nombreuses femmes quittent la consultation de gynécologie sans avoir posé toutes les questions, faute de temps, parce que le doute arrive une fois franchie la porte du cabinet, parce que certains soignants ne donnent pas leur place à l'échange. Les freins peuvent aussi relever des craintes ou préjugés comme des tabous : quand il est question d'infections sexuellement transmissibles, de douleurs chroniques, de freins dans la vie sexuelle, de peurs alimentées par des fausses croyances qui circulent dans l'entourage… Prévention et dépistage  Cette prise en charge en santé sexuelle et reproductive implique un effort d'écoute et de compréhension, qui intègre également un temps de prévention et de dépistage des violences basées sur le genre, pour que puissent s'exprimer, à côté des ressentis et des symptômes des patientes, les émotions, la détresse et les joies, tout comme les appréhensions qui peuvent accompagner la patiente lors de sa consultation…   Avec : Pr Namory Keita, past Président immédiat de la SAGO (Société Africaine des Gynécologues-Obstétriciens). Consultant en matière de santé reproductive et mise en œuvre des programmes de lutte contre les cancers gynécologiques  Dr Sylvie Epelboin, gynécologue obstétricienne, médecin de la Reproduction et coordinatrice du Centre d'Assistance médicale à la Procréation au sein de l'Hôpital Bichat à Paris.  Programmation musicale : ► Singuila feat. Koffi Olomidé – La femme de quelqu'un ► Ao – Talvez.

À l'occasion du congrès Pari(s) Santé Femmes qui se tient du 3 au 5 décembre à Paris, nous parlons de la santé des femmes. Contraception, infections, grossesse et accouchement, infertilité… Des médecins spécialisés en gynécologie-obstétrique répondent aux questions des auditrices.   Le gynécologue et la sage-femme sont les interlocuteurs des femmes, sur de multiples questions de santé, pour la prise en charge de nombreuses affections. Cette fonction d'écoute, de conseil et de soins est l'une des composantes indispensables de la santé féminine aux différents âges de leur vie, en particulier à partir de la puberté.  Des spécialistes à l'écoute des femmes  En consultation, les interrogations et les plaintes peuvent concerner aussi bien l'origine de douleurs et la quête d'un soulagement, que le suivi d'une grossesse, un projet d'enfant et, toujours dans le cadre de la santé reproductive, les questions portant sur la contraception ou la fertilité…   Ces professionnels de santé vont également prendre en charge des maladies et infections spécifiques, comme l'endométriose, des cancers féminins (comme celui du sein ou du col de l'utérus).  Écoute et compétence, sans tabou  De nombreuses femmes quittent la consultation de gynécologie sans avoir posé toutes les questions, faute de temps, parce que le doute arrive une fois franchie la porte du cabinet, parce que certains soignants ne donnent pas leur place à l'échange. Les freins peuvent aussi relever des craintes ou préjugés comme des tabous : quand il est question d'infections sexuellement transmissibles, de douleurs chroniques, de freins dans la vie sexuelle, de peurs alimentées par des fausses croyances qui circulent dans l'entourage… Prévention et dépistage  Cette prise en charge en santé sexuelle et reproductive implique un effort d'écoute et de compréhension, qui intègre également un temps de prévention et de dépistage des violences basées sur le genre, pour que puissent s'exprimer, à côté des ressentis et des symptômes des patientes, les émotions, la détresse et les joies, tout comme les appréhensions qui peuvent accompagner la patiente lors de sa consultation…   Avec : Pr Namory Keita, past Président immédiat de la SAGO (Société Africaine des Gynécologues-Obstétriciens). Consultant en matière de santé reproductive et mise en œuvre des programmes de lutte contre les cancers gynécologiques  Dr Sylvie Epelboin, gynécologue obstétricienne, médecin de la Reproduction et coordinatrice du Centre d'Assistance médicale à la Procréation au sein de l'Hôpital Bichat à Paris.  Programmation musicale : ► Singuila feat. Koffi Olomidé – La femme de quelqu'un ► Ao – Talvez.

Der deutsche Innenminister Alexander Dobrindt hat einen neuen Beraterkreis zur Islamismusbekämpfung ernannt. Was von dem Gremium zu erwarten ist, erklärt die Sozialwissenschaftlerin und kommunale Gleichstellungsbeauftragte Astrid Warburg-Manthey. Welche ideologischen Einflüsse gibt es an Schweizer Hochschulen und Universitäten, und inwieweit leiden dadurch Forschung und Lehre? Dazu gibt unser Schweizer Kollege Phillipp Gut Auskunft. In Österreich gibt es den Geschlechtseintrag „divers“ künftig auch schon für Neugeborene. Wie sinnvoll das ist, darüber sprechen wir mit dem Gynäkologen Dr. Armin Breinl. Und im Kommentar des Tages von Norbert Bolz geht es um die Rentenrebellen im Deutschen Bundestag – werden sie einknicken?

Jede vierte Frau weltweit bricht ihre Schwangerschaft ab. Trotzdem gibt es weiterhin Vorurteile, Falschinformationen und Widerstände. Gynäkologin Alicia Baier will dem etwas entgegensetzen. Von WDR 5.

Gynecology surgery presents unique challenges that require preparation, precision, and strong clinical awareness. In this new First Case: Articles on the Go episode, Lindsay Joyce, MSN, RN, CNOR, shares 10 essential insights every perioperative professional should know before stepping into a GYN case, from preventing nerve injuries and ensuring privacy to managing equipment and verifying complex specimens. If you support gynecology procedures or lead teams who do, this quick, practical rundown is worth your time. Here's what you need to know to set your team and your patient up for success!

La mésinformation en santé n'est pas un phénomène marginal : elle touche toutes et tous, et fragilise particulièrement la santé des femmes. Depuis plus d'un an, une vingtaine d'expertes bénévoles du collectif «Femmes de Santé» se mobilisent pour analyser ce phénomène afin de proposer des solutions concrètes pour agir. Pourquoi les femmes sont-elles particulièrement vulnérables face à ces infox ? Comment lutter contre ces fausses informations qui pullulent sur les réseaux sociaux ? Les fake-news concernent et menacent aujourd'hui chacun d'entre nous. Cette désinformation affecte l'ensemble de notre vie, de nos activités, de nos savoirs et un domaine est particulièrement sensible à ce risque : celui de la santé. Une enquête conduite par le Projet européen SIMODS (Indicateur structurel pour surveiller la désinformation en ligne/2025) montre ainsi que 43% des posts de mésinformation sur les réseaux sociaux concernent la santé !  Identifier les pratiques, les dérives et les dangers… La mésinformation, qu'est-ce que c'est ? Conseils douteux, peurs entretenues, manipulations, escroqueries, raisonnements biaisés et mensonges purs et simples, qui peuvent affecter directement notre intégrité physique et mentale. Cette désinformation a, ces dix dernières années, connu une croissance favorisée par trois facteurs : l'essor du numérique, l'appropriation de ces messages infondés par des personnalités publiques (porte-voix en vérité alternative) et, 3è facteur, la pandémie de Covid-19 et ses conséquences en termes de défiance. Cette crise sanitaire de portée planétaire a débouché sur une vague de remise en question des savoirs, de la science et force de la preuve, renforcée par confusion entre santé et bien-être, retour à la nature et charlatanisme. L'infodémie au féminin  Si cette désinformation nous concerne toutes et tous, un travail collectif (Livre blanc sur la mésinformation en santé, soutenu par le collectif Femmes de Santé), permet de comprendre comment ces infox impactent la santé des femmes : de quelle manière cette mésinformation cible-t-elle les femmes ? Comment identifier les risques engendrés et envisager des solutions ? Aujourd'hui, 51% des publications des réseaux sociaux concernant les vaccins contiennent de la désinformation. On atteint 72% d'affirmations non fondées quand on parle du vaccin HPV, celui qui prévient notamment le cancer du col de l'utérus. À lire aussiComment l'administration Trump alimente le complotisme sur les vaccins Organiser une riposte ambitieuse  Ce travail collectif de professionnelles de santé et de chercheuses imagine des stratégies pour lutter contre la mésinformation et sécuriser leur accès à l'information sur leur santé : un immense chantier qui implique un travail d'éducation pour reconnaître les pièges, identifier et croiser les sources, mieux réguler les pratiques commerciales, encadrer les plateformes numériques, protéger les personnes vulnérables, raconter autrement la santé en valorisant les acteurs communautaires.  Avec : Dr Catherine Bertrand-Ferrandis, coordinatrice de ce livre blanc et membre du Comité scientifique et éthique de Femmes de Santé Imène Kaci, sage-femme libérale, coordinatrice générale et cheffe de projets stratégiques chez Gynélia Santé Femmes, directrice opérationnelle de la société Homemed SAS et Membre active du collectif Femmes de Santé. Créatrice du compte instagram @iksagefemme  Dr Juliette Hazart, médecin addictologue, spécialiste en santé publique, conférencière, auteure de Mon ado est accro aux réseaux sociaux, aux éditions De Boeck supérieur, chargée d'enseignement à l'Université de Lorraine Jessica Leygues, directrice exécutive de l'Institut des cancers des Femmes, de l'Institut Curie.  ► En fin d'émission, nous parlons des premières journées ivoiriennes d'addictologie qui se tiennent du 3 au 5 décembre à l'Institut National de santé publique d'Abidjan, en Côte d'Ivoire. Interview du Pr Samuel Traore, addictologue. Maitre de conférences agrégé de Psychiatrie d'adultes. Chef du service d'Addictologie et d'Hygiène mentale de l'Institut National de Santé Publique à Abidjan, en Côte d'Ivoire. Président de la société de Psychiatrie de Côte d'Ivoire. Programmation musicale : ► Enchantée Julia - Save me ► Nubiyan Twist ft. Fatoumata Diawara - Chasing Shadows. 

La mésinformation en santé n'est pas un phénomène marginal : elle touche toutes et tous, et fragilise particulièrement la santé des femmes. Depuis plus d'un an, une vingtaine d'expertes bénévoles du collectif « Femmes de Santé » se mobilisent pour analyser ce phénomène afin de proposer des solutions concrètes pour agir. Pourquoi les femmes sont-elles particulièrement vulnérables face à ces infox ? Comment lutter contre ces fausses informations, qui pullulent sur les réseaux sociaux ? Les fake-news concernent et menacent aujourd'hui chacun d'entre nous. Cette désinformation affecte l'ensemble de notre vie, de nos activités, de nos savoirs et un domaine est particulièrement sensible à ce risque : celui de la santé. Une enquête conduite par le Projet européen SIMODS (Indicateur structurel pour surveiller la désinformation en ligne/2025) montre ainsi que 43 % des posts de mésinformation sur les réseaux sociaux concernent la santé !  Identifier les pratiques, les dérives et les dangers… La mésinformation, qu'est-ce que c'est ? Conseils douteux, peurs entretenues, manipulations, escroqueries, raisonnements biaisés et mensonge purs et simples, qui peuvent affecter directement notre intégrité physique et mentale. Cette désinformation a, ces dix dernières années, connu une croissance favorisée par trois facteurs : l'essor du numérique, l'appropriation de ces messages infondés par des personnalités publiques (porte-voix en vérité alternative) et, 3ᵉ facteur, la pandémie de covid-19 et ses conséquences en termes de défiance. Cette crise sanitaire de portée planétaire a débouché sur une vague de remise en question des savoirs, de la science et force de la preuve, renforcée par confusion entre santé et bien-être, retour à la nature et charlatanisme. L'infodémie au féminin  Si cette désinformation nous concerne toutes et tous, un travail collectif (Livre blanc sur la mésinformation en santé, soutenu par le collectif Femmes de Santé), permet de comprendre comment ces infox impactent la santé des femmes : de quelle manière cette mésinformation cible-t-elle les femmes ? Comment identifier les risques engendrés et envisager des solutions ? Aujourd'hui, 51 % des publications des réseaux sociaux concernant les vaccins contiennent de la désinformation. On atteint 72% d'affirmations non fondées quand on parle du vaccin HPV, celui qui prévient notamment le cancer du col de l'utérus. À lire aussiComment l'administration Trump alimente le complotisme sur les vaccins Organiser une riposte ambitieuse  Ce travail collectif de professionnelles de santé et de chercheuses imagine des stratégies pour lutter contre la mésinformation et sécuriser leur accès à l'information sur leur santé : un immense chantier qui implique un travail d'éducation pour reconnaître les pièges, identifier et croiser les sources, mieux réguler les pratiques commerciales, encadrer les plateformes numériques, protéger les personnes vulnérables, raconter autrement la santé en valorisant les acteurs communautaires.  Avec : Dr Catherine Bertrand-Ferrandis, coordinatrice de ce livre blanc et membre du Comité scientifique et éthique de Femmes de Santé.  Imène Kaci, Sage-femme libérale, Coordinatrice générale et cheffe de projets stratégiques chez Gynélia Santé Femmes, directrice opérationnelle de la société Homemed SAS et Membre active du collectif Femmes de Santé. Créatrice du compte instagram @iksagefemme  Dr Juliette Hazart, médecin addictologue, spécialiste en santé publique, conférencière, auteure de Mon ado est accro aux réseaux sociaux aux éditions De Boeck supérieur, chargée d'enseignement à l'université de Lorraine.  Jessica Leygues, Directrice exécutive de l'Institut des cancers des Femmes, de l'Institut Curie.  ► En fin d'émission, nous parlons des premières journées ivoiriennes d'addictologie qui se tiennent du 3 au 5 décembre à l'Institut National de santé publique d'Abidjan, en Côte d'Ivoire. Interview du Pr Samuel Traore, Addictologue. Maitre de Conférences Agrégé de Psychiatrie d'adultes. Chef du service d'addictologie et d'hygiène mentale de l'Institut National de Santé Publique à Abidjan en Côte d'Ivoire. Président de la société de psychiatrie de Côte d'Ivoire. Programmation musicale : ► Enchantée Julia - Save me ► Nubiyan Twist ft. Fatoumata Diawara - Chasing Shadows 

On this episode, Dr. Sadaf welcomes UCLA's Rachel Frankenthal, PA-C to the show for a discussion on everything you need to know about hormones after Gyn cancer. Having played an integral role in designing and implementing UCLA's Gynecologic Cancer Survivorship program, Rachel shares her expertise to shine a light on the various challenges that come with Gyn cancer survivorshop. Learn how surgery, chemotherapy, and radiation can induce menopause and result in extreme symptoms, plus why old myths about certain systemic hormones for different cancers are now being debunked.Disclaimer: Anything discussed on the show should not be taken as official medical advice. If you have any concerns about your health, please speak to your medical provider. If you have any questions about your religion, please ask your friendly neighborhood religious leader. It's the Muslim Sex Podcast because I just happen to be a Muslim woman who talks about sex.To learn more about Dr. Sadaf's practice and to become a patient visit DrSadaf.comLike and subscribe to our YouTube channel where you can watch all episodes of the podcast!Feel free to leave a review on Apple Podcasts and share the show!Follow us on Social Media...Instagram: DrSadafobgynTikTok: DrSadafobgyn

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Rund 100.000 Abbrüche gibt’s jedes Jahr in Deutschland – und trotzdem redet kaum jemand offen darüber. Im Blue Moon hat Meret Reh unter anderem mit der Gynäkologin Dr. Alicia Baier gesprochen: Was passiert, wenn ich ungewollt schwanger werde? Und wie unterstütze ich Freund:innen? Unser Podcast-Tipp: Wissen mit Zoé https://www.ardaudiothek.de/sendung/wissen-mit-zo/urn:ard:show:7c88112e3e736672/

+++ Infos zu unseren Sponsoren, Links zu Rabattaktionen etc.: lnkfi.re/einfachganzleben +++ Hormone spielen nicht nur zyklusbedingt im täglichen Leben einer Frau eine große Rolle. Auch der Ursprung überraschend vieler weiblicher Krankheiten liegt in den Hormonen. Bekanntere Beispiele sind Haarausfall, Gewichtsschwankungen oder psychische Probleme. Weniger bekannt ist, dass auch Erkrankungen des Verdauungstrakts, Tinnitus oder Herzstolpern häufig auf hormonelle Veränderungen zurückgehen. Gynäkologin Dr. med. Judith Bildau klärt Frauen jeden Alters auf Basis neuester wissenschaftlicher Erkenntnisse über die hormonellen Vorgänge in ihrem Körper auf – vom Kinderwunsch bis zur Postmenopause. Im Gespräch mit Jutta Ribbrock beantwortet sie Fragen, die ihr über Jahre von ihren Patient:innen gestellt wurden. Außerdem erklärt Dr. Bildau, welche konkreten ganzheitlichen Therapien wirklich helfen: von der richtigen Ernährung über Mikronährstoffe bis hin zu Phytopharmaka und Hormontherapie. Denn in unseren Hormonen steckt auch eine Menge Kraft, die wir für unseren Alltag nutzen können.Zum Weiterhören und Stöbern:www.dr-med-judith-bildau.comwww.instagram.com/dr.med.judith_bildauDr. med. Judith Bildau, Body in Balance – Hormone verstehen und unerklärliche Beschwerden loswerden (Buch und Hörbuch)Die Titelmelodie dieses Podcasts findet ihr auf dem Album balance moods – Ein Tag in der Natur.Noch viel mehr Tipps zu einem bewussten Lebensstil findet ihr auf einfachganzleben.de.Besucht uns auch bei Facebook und Instagram.Ihr habt Fragen, Lob, Kritik oder Anmerkungen? Dann meldet euch auch gern per Mail: einfachganzleben@argon-verlag.deIhr könnt Jutta auch direkt schreiben: jutta@juttaribbrock.deUnd ihr findet sie bei Instagram: @jutta_ribbrock Hosted on Acast. See acast.com/privacy for more information.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Weltweit steht das Recht auf körperliche Selbstbestimmung unter Beschuss. Auch in Deutschland. Denn rechts-konservative Kräfte versuchen seit Jahren, Einfluss auf die Rechtssprechung zu nehmen – immer wieder mit Erfolg.Laura spricht mit der Gynäkologin Alicia Baier darüber, warum Schwangerschaftsabbrüche in Deutschland im Strafgesetzbuch stehen, warum zwei Urteile des Bundesverfassungsgerichts zwar wegweisend, aber nicht demokratisch waren und wie die FDP im letzten Jahr einen wichtigen Schritt hin zu legalen Schwangerschaftsabbrüchen verhindert hat. Alicia Baier ist Autorin von „Das Patriarchat im Uterus“ und Teil des Vorstands von Doctors for Choice.Danke an alle, die den Lila Podcast unterstützenHelft uns, damit unsere Arbeit fair bezahlt werden kann! Alle Infos darüber, wie ihr den Lila Podcast supporten könnt, haben wir für euch hier gesammelt.Aktuelle Werbepartner und weitere Infos zum Podcast.Links und Hinweise„Das Patriarchat im Uterus“, Buch von Alicia BaierAussprache im Bundestag zum Entwurf (inkl. Zitat Beatrix von Storch)Phoenix: Pressekonferenz Merz/Dobrindt (inkl. Zitat Friedrich Merz)SWR: §219a - Infos über Abtreibung verboten? (inkl. Zitat Kristina Hänel)Politik mit Anne Will: Wird der Rechtsstaat zur Kampfzone? (inkl. Zitat Frauke Brosius-Gersdorf)ELSA-Studie AbschlussberichtThe Turnaway StudyWeitere Quelle findet ihr hierWeitere Lila-Folge zum ThemaAbtreibung im Fokus: Was wir aus Polen und aus der Geschichte lernen können (Live von der Dokumentale)Kenne deine (Menschen-)Rechte: Was die UN-Frauenrechtskonvention CEDAW bringtTranskriptWir freuen uns sehr, euch ein Transkript zur Sendung zur Verfügung stellen zu können. Es wurde automatisch erstellt. Ihr findet es auf unserer Website. Hosted on Acast. See acast.com/privacy for more information.

Well, from time to time we cover RANDOM tidbits of information which cover RANDOM questions and/or RANDOM patient care issues that we encounter. In this episode we will cover one OB issue related to recurrent pregnancy loss, one GYN issue related to unilateral breast swelling in a patient with SLE, and one RANDOM life perspective response from a mock interview that I participated in for a residency candidate. Listen in fordetails!1.     Viviana DO; Giugni, Claudio Schenone MD; Ros, Stephanie T. MD, MSCI. Factor V and recurrent pregnancy loss: de Assis, Evaluation of Recurrent Pregnancy Loss. Obstetrics & Gynecology 143(5):p 645-659, May 2024. | DOI: 10.1097/AOG.0000000000005498Unilateral Breast Swelling with SLE: 2.     Voizard B, Lalonde L, Sanchez LM, et al. LupusMastitis as a First Manifestation of Systemic Disease: About Two Cases With a Review of the Literature. European Journal of Radiology. 2017;92:124-131. doi:10.1016/j.ejrad.2017.04.023.3.     Kinonen C, Gattuso P, Reddy VB. Lupus Mastitis:An Uncommon Complication of Systemic or Discoid Lupus. The American Journal of Surgical Pathology. 2010;34(6):901-6. doi:10.1097/PAS.0b013e3181da00fb.4.      Summers TA, Lehman MB, Barner R, Royer MC. Lupus Mastitis: A Clinicopathologic Review and Addition of a Case. Advances in Anatomic Pathology.2009;16(1):56-61. doi:10.1097/PAP.0b013e3181915ff7.5.     Jiménez-Antón A, Jiménez-Gallo D,Millán-Cayetano JF, Navarro-Navarro I, Linares-Barrios M. Unilateral Lupus Mastitis.Lupus. 2023;32(3):438-440. doi:10.1177/09612033221151011.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

Der 34-jährige Demokrat und Muslim Zohran Mamdani ist neuer Stadtpräsident von New York. Ganz zum Ärger von US-Präsident Donald Trump, der bereits im Vorfeld der Wahl angekündigt hat, Mamdani bekämpfen zu wollen. Das Gespräch mit USA-Experte Stephan Bierling. Weitere Themen: Der deutsche Innenminister Alexander Dobrindt hat den islamistischen Verein «Muslim Interaktiv» verboten. Der Verein sorgte im April 2024 mit einer Kundgebung in Hamburg bundesweit für Empörung. Nun hat das Innenministerium daraus die Konsequenz gezogen. Schweizer Ärzte und Ärztinnen müssen derzeit viel Geduld aufbringen, wenn es um ihren Facharzttitel geht. Gynäkologinnen, Psychiater, aber auch Anästhesisten warten monatelang auf die Anerkennung, weil das zuständige Institut, das die Titel herausgibt, überlastet ist. Woran liegt das?

Empfohlener Link: www.intumind.de/podcast-selbsttest In dieser neuen Podcastfolge erfährst du, wie du die hormonellen Veränderungen rund um die Wechseljahre verstehen – und vor allem gelassener damit umgehen kannst. Gemeinsam mit Gynäkologin Dr. Judith Bilder sprechen wir über Anzeichen, natürliche Wege zur Balance und wie du wieder Vertrauen in deinen Körper findest. Diese Folge macht Mut, klärt auf und zeigt: Du musst nicht leiden, wenn du weißt, was in deinem Körper passiert.

In der Diagnostik und Therapie der Endometriose hat sich in den letzten Jahren einiges getan. Die Aktualisierung der Leitlinie zeigt: moderne Endometriose-Versorgung muss mit überholten Vorstellungen aufräumen, Frauen in ihren Beschwerden ernst nehmen und individuell auf sie eingehen. PD Dr. med. Stefanie Burghaus, Gynäkologin und Leitlinien-Koordinatorin, erklärt im Podcast, was das für die Praxis bedeutet.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog This Blog contains dialogue of a sexual nature In my 29-year history of practicing gynecology and 23 years of practicing hormone replacement medicine, there have always been a few questions that only the bravest and most comfortable patients would ask me during a well-woman visit or consultation. During the next few weeks, I will dedicate my blog to those usually unanswered questions, but most probably those questions that women are too embarrassed to ask. The first question is asked in many forms, but the general idea of the question is:” What should I do if I think my vaginal area smells weird?”  “Smelling weird” is a common description that can imply many things, so I will outline what I ask my patients to gather enough information to provide them with a medically relevant answer. What does it smell like? Yeasty, like baked bread? Sweaty-like body odor? Sour- like a towel that has been we too long? Musky – like the musk type of perfumes? Urine? everyone knows what that smells like Old people in a nursing home? OR “Like something is dead in there?” “Like Fish?” These are the actual descriptions that I have received in response to my question, and they all identify different. In case some of you are worriers, I will start with the fact that vaginal odors 1-6 are likely due to a minor infection, either an overgrowth of yeast, or the fact that you don't air out that area at night which makes yeast and bacteria grow in the warm environment between your legs or under the covers. Vaginal odors 7 and 8 are more serious and require treatment. I will first discuss the most important conditions based on their odors. These can be quite dangerous if ignored. Let me start by addressing odors 7 and 8. Odor # 7. If your vagina smells foul, like “something is dead in there,” you should probably make an appointment with your GYN. It could result from something as simple as a tampon that was “lost” in the vagina, leading to bacteria growing from menstrual blood and semen.  This is a common cause of such vaginal odor. The GYN will need to use an instrument to grasp the tampon and remove it. She will then prescribe an antibiotic to treat the infection that has developed. While there's no harm in removing it, leaving it in place can lead to a serious pelvic infection. If your doctor doesn't find a tampon and this odor is confirmed by her, then she will do bacterial cultures and a pap to look for cervical cancer or endometrial cancer. It is important that you don't ignore this odor.  It won't get better on its own. Odor #8. If your vagina smells like fish it is likely an infection with a bacteria called hemophilous vaginalis, or from Trichomonas (“Trick”). Hemophilus can be caused by wiping back to front (the wrong way), which allows rectal bacteria to enter the vagina. Additionally, Hemophilus can be introduced into the vagina during intercourse. In these two cases, it is not considered a venereal infection– NOT an infection you acquired from your sexual partner. However, Hemophilus can be a venereal infection that you contract from a sexual partner if he acquired it from someone else and transmitted it to you! The treatment is essentially the same: a medication called Flagyl or metronidazole, taken three times a day for 7-10 days. If your partner has it too, he needs to take the medication at the same time so you don‘t keep passing it to each other. These infections require examination and testing to receive an antibiotic. The last possible cause of a fishy-smelling vagina is Trichomonas, a parasite that produces a significant amount of thin, greenish discharge along with a fishy odor. It is sexually transmitted, and both partners should be treated.  He should also have his other contacts treated. The group of infections in #8 is treatable and curable with medical help. Another quality of Hemophilus and Trichomonas is that if you have nitrazine pH paper and test the discharge with it, it will turn the paper dark blue.  Dark blue means go to the GYN! We'll start back up at 1-6 discussing the causes of “funny smelling discharge. ” These are the least likely to be serious infections. I need to provide some initial information before I discuss the various reasons for vaginal odor. First, there is always a slight odor that is uniquely yours. You shouldn't try to eliminate all signs of vaginal odor because it results from a combination of yeast, good bacteria, estrogen, testosterone, and progesterone, which help protect your vagina and vulva, the area surrounding the vagina.  Changes in hormones such as pregnancy, menopause, hormone replacement therapy, diet, antibiotics, and dehydration can alter the vaginal smell and discharge. The yeasty odor that resembles baked bread comes from normal yeast present in the vagina. Some women naturally have this odor. It becomes a concern only when it is accompanied by itching and a significant amount of white discharge. These yeast infections can occur after taking antibiotics that eliminate good bacteria.  They may also arise when blood sugar levels are elevated, as seen in diabetics or prediabetics. The pH paper will not change color.  Treatment involves yeast medication, which can be either vaginal or oral, along with oral probiotics and sometimes vaginal probiotics to help restore the good bacteria. If you are diabetic, you may experience yeast infections until your blood glucose levels are normalized.   Sweaty-like body odor.The vagina can develop body odor from sweat that fosters the same bacteria found under your armpits.  This matter is simple.  Change out of wet swimsuits, wash gently with the same soap you use for the rest of your body, and allow your vagina to dry by sleeping without underwear.   Sour like a towel that has been wet too long. The ability to detect sour odors is genetically determined. You may not notice it, but your significant other might, or you may smell his clothes that have this odor, while he doesn't.  Either way, it is caused by bacteria from sweaty, damp clothes thrown into a hamper, allowing fungus and bacteria to grow. For some reason, you then wear these clothes, and your vagina ends up harboring the same jungle of bacteria and fungus.  This one is easy: air out clothes before wearing them, avoid putting on garments that are not clean, and wash these clothes in warm water to eliminate the microbes. You may need a doctor's visit for diagnosis and treatment.   Musky -you know, like the musk type of perfumes. A musky smell is the natural scent of fertile women with testosterone, especially when they are sexually stimulated. This is not an infection; it is the normal sexual scent of attraction. This odor usually diminishes with menopause or when you are on the pill and your testosterone levels decrease.   Like urine. The smell of urine is usually caused by leaking urine, poor wiping, or wearing a pad that absorbs leaking urine. It can precede a yeast infection because urine wetness encourages the growth of yeast. Treating urine leakage is imperative for resolving this issue. Options include surgery, Emsella magnetic pelvic floor strengthener, or a pessary. All of these can be discussed with your doctor when you inform them that you experience this odor consistently.   Like Elderly individuals in a nursing home? Sadly, nursing homes do have a characteristic odor; it is a combination of urine and cleaning chemicals, but there is something more. Elderly people who lack hormones have lost protective bacteria and exhibit a dominant odor of deterioration. This is what the vagina smells like without hormones and the beneficial bacteria they support. This is a smell that many women ask me about after menopause when they don't take hormones. The only way to return the odor to normal is to reinstate hormones.   If you have other vaginal odors I have not addressed, then send your email questions to podcast@biobalancehealth.com.  I pray you will trust your gynecologist enough to ask any questions you need to understand your own body. I hope I have provided you with some material to reflect on and compare to help answer your questions.

What do you look for when selecting a personal doctor? Years of experience? Hospital affiliation? Expertise and specialty? Martha's latest guest began her journey into medicine as a young student with a passion for science, biology, and the deep desire to impact the lives of others. With more than 40 years in practice and medical research, Dr. Carin Behar is changing the way women look at health and wellness. As a general internist and the medical director of the Joan Tisch Center for Women's Health, Dr. Behar treats a wide variety of conditions, with a focus on preventive care and health maintenance. She caters to the unique needs of women, consolidating annual medical and GYN exams, mammograms, bone density, medical subspecialties, women's orthopedics, dermatology, and cancer risk, all in one place. In this podcast, Dr. Behar talks to Martha about her approach to women's care, the latest advice on women's imaging and testing, the importance of mental health, and what she wishes all her female patients to know as they enter their later years. Be sure to listen. See omnystudio.com/listener for privacy information.

When radiology meets surgery, endometriosis care becomes more precise, personalized, and proactive. In this BackTable OBGYN Brief, host Dr. Mark Hoffman is joined by Dr. Wendaline VanBuren, an associate professor of radiology at Mayo Clinic, and Dr. Tatnai Burnett, a minimally invasive GYN surgeon at Mayo Clinic, to discuss the complexities of diagnosing and managing endometriosis. The discussion covers the roles of advanced imaging techniques like MRI and ultrasound, the importance of pre-surgical planning, and the need for multidisciplinary collaboration. They share their approach to managing symptomatic and asymptomatic patients, the use of hormonal treatments, and the significance of monitoring potential malignant transformations in endometrioma cases. The episode underscores the critical role of imaging in planning effective surgical interventions for patients while highlighting the progression of endometriosis management protocols. TIMESTAMPS 00:00 - Introduction  01:07 - Discussing Endometriosis Management 02:18 - Imaging Techniques and Their Importance 04:24 - Interdisciplinary Collaboration 05:40 - Advanced Imaging Protocols 08:12 - Monitoring and Follow-Up Strategies 08:50 - Concerns About Malignancy 11:04 - Future Directions CHECK OUT THE FULL EPISODE OBGYN Ep. 69 https://www.backtable.com/shows/obgyn/podcasts/69/imaging-protocols-to-guide-endometriosis-treatment

Today, I am honored to connect with Rachel Frankenthal, a board-certified physician assistant with a master's degree in public health, specializing in gynecologic oncology. Rachel is on the staff at UCLA Health, where she treats women with gynecologic cancers and women at high risk for uterine or ovarian cancer due to genetic mutations or a strong family history.  In our discussion, we unpack GYN oncology, covering the five GYN cancers, why ovarian cancer is the silent killer, and the labs and ultrasounds to help screen for ovarian cancer. We dive into genetics, including BRCA mutations and Lynch syndrome, appropriate genetic counseling, and what Rachel considers when dealing with younger patients still at peak fertility versus older patients. We explore the importance of HRT utilization for cancer previvors, the effects of pelvic radiation, vaginal and sexual health, and what thriving looks like after cancer. Rachel shares her stepwise approach to hot flashes, and we also discuss the importance of lifestyle, bone health, and specific research on the benefits of GLP-1s for women with ovarian and endometrial cancer.  This conversation is especially relevant as we are in GYN and Ovarian Cancer Awareness Month. I look forward to having Rachel back again, hopefully later this fall, to discuss the use of hormone replacement therapy with GYN oncology survivors. IN THIS EPISODE, YOU WILL LEARN: How the lack of effective screening makes ovarian cancer hard to detect due to  How BRCA and Lynch syndrome influence cancer risk and treatment choices The benefits of HRT for cancer previvors Risks that arise from surgical menopause without sufficient or properly dosed HRT Why less than 50% of eligible women actually receive hormone therapy How pelvic radiation impacts menopause, vaginal tissue, bladder, and GI health The support that is crucial for cancer survivors after pelvic radiation Lifestyle factors to improve cancer treatment outcomes   Rachel shares her stepwise approach to managing hot flashes  What GLP-1 research reveals about reducing ovarian cancer mortality and endometrial cancer risk Bio: Rachel Frankenthal Rachel Frankenthal is a board-certified and licensed Physician Associate and Menopause Society Certified Practitioner with a Master's in Public Health. She specializes in gynecologic oncology, treating women with gynecologic cancers as well as women at high risk for uterine or ovarian cancer due to genetic mutations. Rachel has a special passion for menopause and midlife women's healthcare. She developed the menopause clinic for gynecologic cancer survivors and previvors at UCLA and has played an integral role in developing the GYN cancer survivorship program, where she teaches the weekly yoga and meditation class. Rachel lectures at UCLA and across the country on the importance of comprehensive menopause care in cancer survivorship and has created a course on hormone therapy for gynecologic cancer survivors through the Heather Hirsch Academy. In addition to being a medical practitioner, Rachel is a certified yoga and Pilates instructor, a prior Broadway performer, and an advocate for integrative, holistic health. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Rachel Frankenthal On Instagram

When radiology meets surgery, endometriosis care becomes more precise, personalized, and proactive. In this BackTable OBGYN Brief, host Dr. Mark Hoffman is joined by Dr. Wendaline VanBuren, an associate professor of radiology at Mayo Clinic, and Dr. Tatnai Burnett, a minimally invasive GYN surgeon at Mayo Clinic, to discuss the complexities of diagnosing and managing endometriosis. The discussion covers the roles of advanced imaging techniques like MRI and ultrasound, the importance of pre-surgical planning, and the need for multidisciplinary collaboration. They share their approach to managing symptomatic and asymptomatic patients, the use of hormonal treatments, and the significance of monitoring potential malignant transformations in endometrioma cases. The episode underscores the critical role of imaging in planning effective surgical interventions for patients while highlighting the progression of endometriosis management protocols. TIMESTAMPS 00:00 - Introduction  01:07 - Discussing Endometriosis Management 02:18 - Imaging Techniques and Their Importance 04:24 - Interdisciplinary Collaboration 05:40 - Advanced Imaging Protocols 08:12 - Monitoring and Follow-Up Strategies 08:50 - Concerns About Malignancy 11:04 - Future Directions CHECK OUT THE FULL EPISODE OBGYN Ep. 69 https://www.backtable.com/shows/obgyn/podcasts/69/imaging-protocols-to-guide-endometriosis-treatment

Persistent Genital Arousal Disorder (PGAD) is a rare and often misunderstood condition that involves unwanted, persistent genital sensations that don't resolve with one or more orgasms. Left untreated, PGAD can deeply affect mental health, body wellness, and quality of life.On this episode of Sky Women's Health Podcast, I'm joined by Dr. Sameena Rahman, founder of the GYN and Sexual Medicine Collective and host of Gyno Girl Presents: SEX, DRUGS & HORMONES, to explore:How PGAD is defined and diagnosedThe workup for underlying causesMultidisciplinary treatment optionsHow sexual wellness, hormones, and mental health intersectDr. Sameena Rahman:

Dr. Monica Prasad-Hayes explains GYN oncology, or treatment of gynecologic cancers. Dr. Hayes is an associate professor of OB-GYN, director of the GYN oncology fellowship at Mount Sinai Hospital, and a practicing GYN oncologist. She explains testing, treatment, and symptoms of ovarian cancer, cervical cancer, and more.